



JUN 8 - 2005

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Fray Adib
President
Myotronics-Noromed, Incorporated
15425 53rd Ave South
Tukwila, Washington 98188

Re: K922456
Trade/Device Name: K6-1 Diagnostic System
Regulation Number: 21 CFR 890.1375
Regulation Name: Diagnostic electromyograph
Regulatory Class: II
Product Code: KZM and NFS
Dated: December 23, 1992
Received: December 24, 1992

Dear Mr. Adib:

This letter corrects our substantially equivalent letter of April 15, 1994, regarding the classification of your device which was incorrectly identified as "unclassified."

We have reviewed your Section 510(k) notification of intent to market the device referenced above and have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class I (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, FDA will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note: this response to your pre-market notification submission


Page 2 – Ms. Patterson

does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. **An** FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, **permits** your device to proceed to the market, but it does not mean that FDA **approves** your device. Therefore, you may not promote or in any way represent your device or its labeling as being approved by FDA.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the **Office** of Compliance at (240) 276-0115. Additionally, for questions on the promotion and advertising of your device, please contact the **Office** of Compliance at (301) 594-4639. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Chiu S. Lin, PhD". The signature is written in a cursive style with a large initial "C".

Chiu S. Lin, PhD

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health